Literature DB >> 11186170

Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.

G Wolf1, R Hildenbrand, C Schwar, R Grobholz, M Kaufmann, H J Stutte, K Strebhardt, U Bleyl.   

Abstract

Previous data have shown that the mRNA-expression of the serin/threonine-kinase polo-like kinase (PLK) is closely correlated with the survival of patients suffering from a subset of malignant tumors. PLK-mRNA and protein-expression are restricted to cells in the cell cycle. PLK-mRNA-transcripts are highly abundant in proliferating cells; no gene expression is found in G0-phase cells. Here we investigated the mRNA- and protein-expression of PLK- and estrogen-receptor (ER) in human breast-carcinoma by northern-blotting, RT-PCR and immunohistochemistry. The expression of MIB-I was determined on serial sections. Analysis of the immunohistochemical data revealed a close correlation between the ER and PLK-expression (r = 0.677; p = 0.001, n = 30). No relationship between the mRNA-expression of ER and PLK was found. Furthermore, no correlation for the protein expression of PLK and MIB-I exists. The influence of estrogen (ES) is known to have proliferative potential. The expression of ER correlates with the ES-plasma-level. In addition, the hormone cycle of premenopausal women undergoes rapid vacillations with varying effects on the proliferating tumor cells, e.g., growth induction. Our results therefore show that ER-expression is not only of therapeutic value for the clinician, but it may also be a tool for determining the tumor proliferation index more precisely by integrating the hormone-mediated proliferation stimulus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186170     DOI: 10.1016/S0344-0338(00)80107-7

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  33 in total

1.  Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.

Authors:  Tetsuo Ito; Fumiaki Sato; Takatsugu Kan; Yulan Cheng; Stefan David; Rachana Agarwal; Bogdan C Paun; Zhe Jin; Alexandru V Olaru; James P Hamilton; Florin M Selaru; Jian Yang; Nobutoshi Matsumura; Kazuharu Shimizu; John M Abraham; Yutaka Shimada; Yuriko Mori; Stephen J Meltzer
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

2.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

Review 3.  Targeting polo-like kinase 1 in acute myeloid leukemia.

Authors:  Joseph M Brandwein
Journal:  Ther Adv Hematol       Date:  2015-04

4.  [Endolaryngeal swelling with dyspnoea].

Authors:  T Schrom; J Berl; G Wolf; H Scherer
Journal:  HNO       Date:  2005-06       Impact factor: 1.284

Review 5.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

6.  LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.

Authors:  Kazim Sahin; Mehmet Tuzcu; Mehmet Yabas; Cemal Orhan; Nurhan Sahin; Ibrahim H Ozercan
Journal:  Invest New Drugs       Date:  2017-11-15       Impact factor: 3.850

7.  Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Authors:  Brian D Cholewa; Mary A Ndiaye; Wei Huang; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Lett       Date:  2016-10-25       Impact factor: 8.679

8.  Borealin is repressed in response to p53/Rb signaling.

Authors:  Dipali A Date; Cara J Jacob; Mike E Bekier; Andrew C Stiff; Mark W Jackson; William R Taylor
Journal:  Cell Biol Int       Date:  2007-07-15       Impact factor: 3.612

9.  Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Authors:  Neil E Bhola; Valerie M Jansen; Sangeeta Bafna; Jennifer M Giltnane; Justin M Balko; Mónica V Estrada; Ingrid Meszoely; Ingrid Mayer; Vandana Abramson; Fei Ye; Melinda Sanders; Teresa C Dugger; Eliezer V Allen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

Review 10.  Study of apoptosis-related interactions in colorectal cancer.

Authors:  Himanshu Arora; Rehana Qureshi; M A Rizvi; Sharad Shrivastava; Mordhwaj S Parihar
Journal:  Tumour Biol       Date:  2016-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.